Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer

被引：0
|
作者：
Xiaohe Su
Kaifeng Jin
Qiji Guo
Ziyue Xu
Zhaopei Liu
Han Zeng
Yiwei Wang
Yu Zhu
Le Xu
Zewei Wang
Yuan Chang
Jiejie Xu
机构：
[1] Fudan University,NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences
[2] Fudan University,Department of Urology, Zhongshan Hospital
[3] Fudan University Shanghai Cancer Center,Department of Urology
[4] Shanghai Jiao Tong University School of Medicine,Department of Urology, Shanghai Ninth People’s Hospital
[5] Shanghai Jiao Tong University School of Medicine,Department of Urology, Ruijin Hospital
来源：
British Journal of Cancer | 2024年 / 130卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：852 / 860
页数：8
相关论文
共 50 条
  • [1] Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer
    Su, Xiaohe
    Jin, Kaifeng
    Guo, Qiji
    Xu, Ziyue
    Liu, Zhaopei
    Zeng, Han
    Wang, Yiwei
    Zhu, Yu
    Xu, Le
    Wang, Zewei
    Chang, Yuan
    Xu, Jiejie
    BRITISH JOURNAL OF CANCER, 2024, 130 (05) : 852 - 860
  • [2] TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer
    Liu, Zhaopei
    Zeng, Han
    Jin, Kaifeng
    Yu, Yanze
    You, Runze
    Zhang, Hongyi
    Liu, Chunnan
    Su, Xiaohe
    Yan, Sen
    Chang, Yuan
    Liu, Li
    Xu, Le
    Xu, Jiejie
    Zhu, Yu
    Wang, Zewei
    BRITISH JOURNAL OF CANCER, 2022, 126 (09) : 1310 - 1317
  • [3] TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer
    Zhaopei Liu
    Han Zeng
    Kaifeng Jin
    Yanze Yu
    Runze You
    Hongyi Zhang
    Chunnan Liu
    Xiaohe Su
    Sen Yan
    Yuan Chang
    Li Liu
    Le Xu
    Jiejie Xu
    Yu Zhu
    Zewei Wang
    British Journal of Cancer, 2022, 126 : 1310 - 1317
  • [4] TP53 DISRUPTIVE MUTATION PREDICTS PLATINUM-BASED CHEMOTHERAPY AND PD-1/PD-L1 BLOCKADE RESPONSE IN UROTHELIAL CARCINOMA
    Jin, Kaifeng
    Liu, Zhaopei
    Wang, Zewei
    JOURNAL OF UROLOGY, 2024, 211 (05): : E869 - E870
  • [5] TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma
    Jin, Kaifeng
    Xu, Jingtong
    Su, Xiaohe
    Xu, Ziyue
    Li, Bingyu
    Liu, Ge
    Liu, Hailong
    Wang, Yiwei
    Zhu, Yu
    Xu, Le
    Zhang, Weijuan
    Liu, Zhaopei
    Wang, Zewei
    Chang, Yuan
    Xu, Jiejie
    JOURNAL OF PATHOLOGY, 2024, 263 (02): : 139 - 149
  • [6] TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma
    Kaifeng, J.
    Zewei, W.
    Zhaopei, L.
    Jiejie, X.
    EUROPEAN UROLOGY, 2024, 85 : S1737 - S1738
  • [7] Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients
    Chunnan Liu
    Zhaopei Liu
    Kaifeng Jin
    Han Zeng
    Fei Shao
    Yuan Chang
    Yiwei Wang
    Le Xu
    Zewei Wang
    Yu Zhu
    Weijuan Zhang
    British Journal of Cancer, 2022, 127 : 1718 - 1725
  • [8] Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients
    Liu, Chunnan
    Liu, Zhaopei
    Jin, Kaifeng
    Zeng, Han
    Shao, Fei
    Chang, Yuan
    Wang, Yiwei
    Xu, Le
    Wang, Zewei
    Zhu, Yu
    Zhang, Weijuan
    BRITISH JOURNAL OF CANCER, 2022, 127 (09) : 1718 - 1725
  • [9] Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
    Bai, Jie
    Gao, Zhitao
    Li, Xiang
    Dong, Liang
    Han, Weidong
    Nie, Jing
    ONCOTARGET, 2017, 8 (66) : 110693 - 110707
  • [10] Drug response to PD-1/PD-L1 blockade: based on biomarkers
    Chen, Qi
    Li, Tianhe
    Yue, Wentao
    ONCOTARGETS AND THERAPY, 2018, 11 : 4673 - 4683
12345